|  |
| --- |
| **Cover letter**  |

Delete the text in green color and replace it with your own text if any.

To, Editor-in-Chief, International pharmacy Acta

 [insert data here –Day Month Year]

Re: submission of Manuscript to International Pharmacy Acta for publication

Dear Editor,

I/We would like my/our submitted manuscript entitled “[insert title of your manuscript here]” to be considered for publication in the International Pharmacy Acta as [insert article type here for example, original research article, systematic review, meta-analysis, clinical trial] article.

I/We hereby confirm that I/we have studied the IPA guidelines and I/we confirm that the submission follows all IPA protocols and standards for manuscript, and I/we authors of the above mentioned manuscript accept all of IPA protocols and format in this regards.

[Briefly explain the content presented in this manuscript in your own word including the significance of your work and novelties presented in your work.]

Please state any potential conflict of interest such as:

1) Funding and financial connections and support, including any resources that any of this manuscript co-authors might have received directly or indirectly for this job or publication

2) Any personal relationship, rivalries, academic competition

3) Any intellectual properties

In case of the lack of any kind of conflict of interests of any of co-authors mentioned in this manuscript, please nil or none declared.

We give the rights to [insert corresponding author´s name] who on behalf of all authors will communicate with the IPA from this point onward and will make necessary changes as per the IPA requests. So please address all correspondence to:

 [insert contact address, telephone and fax numbers, and e-mail address of corresponding author]

|  |
| --- |
| **Title Page** |

|  |  |
| --- | --- |
| **Manuscript title:** | Titles should be concise, specific, and informative and should contain the key points of the work and questions and declarative sentences should be avoided. |
| **Running title:** | a short version of the title (up to 40 characters including spaces) |
| **Authors:** | List authors in the order in which they are to appear in the byline of the article (First name Middle name Last name).Authors should be identified by superscripts and corresponded to the related affiliation. Additionally, put an asterisk in front of the name of the corresponding author. For example: [Guobao Wei](http://www.sciencedirect.com/science/article/pii/S0142961203011542)[a](http://www.sciencedirect.com/science/article/pii/S0142961203011542#AFFA), [Peter X. Ma](http://www.sciencedirect.com/science/article/pii/S0142961203011542)[b](http://www.sciencedirect.com/science/article/pii/S0142961203011542#AFFB), [c](http://www.sciencedirect.com/science/article/pii/S0142961203011542#AFFC),\* |
| **Authors**’ **Affiliations:** | For examplea Pharmaceutical Sciences of Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. |
| **\*Corresponding author:** | The corresponding author is the one individual of authorship group who takes primary responsibility for communication with the journal during the manuscript submission, peer review, and publication process, and typically ensures that requirements requested by the journal, such as providing ethics committee approval, gathering conflict of interest forms and statement are properly completed. Also, The corresponding author should be available after publication to respond to critiques of the work and cooperate with any requests from the journal for data or additional information and questions about the paper arise after publication.First name Middle name Last name; Academic degree; AffiliationTel:Fax:Email:Mailing address: |

|  |
| --- |
| **Abstract** |

Abstracts should not exceed 500 words unless listed otherwise. For the ease of fast review and page layout, all articles except the review articles must follow one of the specific structured Abstract formats.

**for Clinical Research Article:**

|  |  |
| --- | --- |
| **Abstract:** | **Introduction:****Methods and Results:****Conclusions:**For more details refer to the relevant reporting guidelines of each specific clinical study designs, such as [CONSORT](http://www.consort-statement.org/) for randomized controlled trials, [TREND](http://www.cdc.gov/trendstatement/) for non-randomized trials, STROBE for descriptive or observational studies and other specialized guidelines as appropriate. |
| **Fundings:** | Funding sources should be listed separately after the Abstract to facilitate proper display and indexing for search retrieval by MEDLINE. |
| **Keywords:** | 3 to 10 key words or phrases that author believes are representative of main content of the article. it is recommended to select terms from the medical subject headings list of [nlm.nih.gov/mesh](http://127.0.0.1:800/CA_%20A%20Cancer%20Journal%20for%20Clinicians/www.nlm.nih.gov/mesh/default.htm) (MeSH terms) but they can be of the authors’ own choice. |

|  |
| --- |
| **Manuscript Main Text** |

**for Clinical Research Article:**

For each specific clinical study designs refer to the relevant reporting guidelines of them, such as [CONSORT](http://www.consort-statement.org/) for randomized controlled trials, [TREND](http://www.cdc.gov/trendstatement/) for non-randomized trials, STROBE for descriptive or observational studies. Please include the elements suggested by the checklist of relevant reporting guidelines.

1. **Introduction**

**1.1. Subtitle**

**1.2. Subtitle**

Reference numbers in the text should be inserted immediately after punctuation (with no word spacing). Where more than one reference is cited, these should be separated by a comma, for example: [2,3,4]

For sequences of consecutive numbers, give the first and last number of the sequence separated by a hyphen, for example: [5-7]

1. **Methods**

Please indicate which guideline you have referred to. For all clinical trial submissions, Registration details and details of prior approval for human subjects research by an institutional review board (IRB) or equivalent ethics committee(s) must be reported in this section.

1. **Results**
2. **Discussion and Conclusions**

Registration number and name of trial registry:

[List of abbreviations used](http://www.darujps.com/authors/instructions/lettertotheeditor#formatting-abbreviations) (if any)

|  |
| --- |
| **Acknowledgements/ Conflict of Interest /Sources of support , fundings declaration, Ethics and Authors' ORCIDs** |

**Acknowledgements**: This section should describe all relevant contributions of persons who have contributed to the work but met fewer than for authorship criteria based on ICMJE recommendation and are not a co-author on the manuscript.

**Conflict of Interest:** Conflict of interest information for each author needs to be part of this section.

**Sources of support and fundings declaration:** All financial and material support for the research, including grants, equipment, drugs, and/or other support that facilitated conduct of the work, should be listed. If the work had no specific funding, this should be explicitly stated.

**Ethics**

**Authors' ORCIDs**

|  |
| --- |
| **References** |

● Authors are responsible for the accuracy and completeness of their references and for correct text citation

● Reference to a paper accepted but not yet published can be listed as ‘‘In press’ or "Forthcoming". Information from manuscripts submitted but not accepted should be cited in the text as “unpublished observations” with written permission from the source.

**Style and Format**

References should follow the instructions offered by [The NLM Style Guide for Authors, Editors, and Publishers](https://www.nlm.nih.gov/bsd/uniform_requirements.html)

 and you can find sample references in webpage <http://www.nlm.nih.gov/bsd/uniform_requirements.html>. Details are in [Citing Medicine](http://www.ncbi.nlm.nih.gov/books/NBK7256/) (at <http://www.nlm.nih.gov/citingmedicine>). Style files are available for use with bibliographic management software [EndNote style file](http://www.biomedcentral.com/download/endnote/biomedcentral.ens).

Reference numbers in the text should be inserted immediately after punctuation (with no word spacing). Where more than one reference is cited, these should be separated by a comma, for example: [2,3,4]

For sequences of consecutive numbers, give the first and last number of the sequence separated by a hyphen, for example: [5-7]

|  |
| --- |
| **Tables and Table Titles** |

Please start this component on a new page.

The table number shoud be followed by a brief descriptive title at the top of table .

• Do not embed tables as graphic files.

• Each column should have a heading and the units of measurement should be given in parentheses in the heading.

• Obtain written permission to reproduce previously published tabular material. Credits for the reproduced work are included as a footnote to the table and must include author(s), title, either publisher and city (and country) or periodical name, volume, page, and year. Signed permission forms must be sent to the *IPA* Editorial Office upon submissions.

• If a table exceeds one manuscript page, include table number, ‘‘continued,’’ and table subheadings on each page.

**Abbreviation:**

• Define all abbreviations and symbols used in the table in footnotes to the table ( immediately below the table).

• Any necessary explanations such as the nature of values should be noted in a Footnote to table.

• Use superscript letters (not symbols), and asterisks (\*) for significance.

Example:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Object** | **Heading A (units of measurement)** | **Heading B** | **Heading C\*** | **Heading D\*\*** |
| **A** | 43 | - | 92a | 105 |
| **B** | 42 | 75 | - | 101 |
| **C** | 51 | 64 | 84 | 99 |
| **D** | - | 43 |  | 56 |
| **E** | - | 74 | - | 112 |
| **F** | 35 | 72 | - | - |

**\***

**\*\***

|  |
| --- |
| **Figures and Figure Legends** |

• please start embedding figures on new page of Microsoft Word manuscript document and Call out all figures in the text.

• Figures and line art should be provided only as TIFF, BMP, JPEG, GIF, PNG, EPS , PSD or Post Script preferably from PhotoShop or Illustrator software.The best formats are TIFF and JPEG.

•Electronically submitted figures should be of high resolution:

* Color, 300 d.p.i. minimum; we prefer RGB for optimal rendering online, and, if possible, recommend that authors use sRGB IEC61966-2.1 when preparing files
* Grayscale, 600 d.p.i. minimum for blots and black & white photographs
* Line art, 1200 d.p.i. minimum for graphs and illustrations

•Histograms should be presented in a simple, two-dimensional format, with no background grid.

•Any lettering in the figures should be large enough to stand photographic reduction and use 9-pt to 12-pt Helvetica or Arial font for them.

• Mask any patient identification in photographs; otherwise, a signed permission statement is required for identifiable patients (please see Permissions section).

• Figures should be on a white background. Do not use overall background shading in figures. Do not use gray-shaded bars in graphs—use bars with solid, open, or hatched fill.

• Figures with multiple parts should be labeled and referred to as (a), (b), (c), etc. Authors should prepare their figures for either one column width (80 mm) or the entire page width (170 mm). The maximum height is 110 mm.

• *IPA* reserves the right to resize and/or crop figures to fit the journal’s format where appropriate. Authors will see a proof of figures.

• Figure legends should include the figure number, a brief title and a brief description of the figure.